modotuximab
mAbexperimental
Modotuximab is a chimeric monoclonal antibody designed for the treatment of cancer. It acts as an immunomodulator and binds to HER1. — Wikipedia
Clinical trial activity
4 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
3
Phase 3
2
Phase 4
0
Earliest trial started Sep 30, 2018 (NCT03549338)
Timeline
Indications
Mechanism of action
- Epidermal growth factor receptor erbB1ANTAGONIST
Epidermal growth factor receptor erbB1 antagonist
Epidermal growth factor receptor erbB1 inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaModotuximab ↗
- ChEMBLCHEMBL3989988 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05223673 | Phase 3 | Apr 21, 2022 | Servier, University of Campania Luigi Vanvitelli |
| NCT05162755 | Phase 1 | Oct 15, 2021 | Servier, The START Center for Cancer Care |
| NCT03717038 | Phase 3 | Feb 28, 2019 | Symphogen A/S, Universidad Autonoma de Barcelona |
| NCT03549338 | Phase 2 | Sep 30, 2018 | Symphogen A/S, University of Texas at Houston |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Servier | For profit | 2 | 2 | 2 | 2021 |
| Symphogen A/S | For profit | 2 | 2 | 2 | 2018 |
| The START Center for Cancer Care | Academic/Hospital | 1 | 0 | 1 | 2021 |
| Universidad Autonoma de Barcelona | Academic/Hospital | 1 | 0 | 1 | 2019 |
| University of Campania Luigi Vanvitelli | Academic/Hospital | 1 | 0 | 1 | 2022 |
| University of Texas at Houston | Academic/Hospital | 1 | 0 | 1 | 2018 |
6 organizations
Page 1 / 1